Category Archives: Psoriasis

THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present several studies related to brodalumab, Enbrel (etanercept) and ABP 501 (adalimumab biosimilar) at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to delivering medicines that may help to improve the lives of people suffering from devastating dermatologic diseases.

"As a pioneer in psoriasis research and development, we are pleased to share scientific insights from our growing dermatology portfolio that may help improve care for the millions of people worldwide1 affected by this serious skin disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The data being presented at this year's congress demonstrate the breadth and depth of our biologics expertise in advancing treatments that address critical unmet needs for patients living with psoriasis."

Brodalumab data to be presented include an exploratory analysis of the Phase 2 trial evaluating efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis patients with prior biologic exposure, along with an analysis from the open-label extension study of that same Phase 2 study evaluating patient response to treatment after nearly three years. Brodalumab is being co-developed by Amgen and AstraZeneca. Kyowa Hakko Kirin, which has an exclusive license to develop and commercialize brodalumab in Japan, China and certain other Asian countries, will present efficacy and safety data from its Phase 2 study evaluating brodalumab in Japanese patients with moderate-to-severe plaque psoriasis.

ENBREL data focus on step-down dosing compared with a high-dose regimen and patient-reported outcomes of treatment with ENBREL compared to treatment with ENBREL in combination with topical therapies. Additional data include the functional equivalence of proposed biosimilar ABP 501 to adalimumab and an analysis of the incidence of symptoms such as itching and pain in patients with psoriasis.

SELECTED ABSTRACTS OF INTERESTAbstracts are available to registered journalists at http://www.eadvamsterdam2014.org/press and updated data will be presented at the meeting.

Brodalumab Abstracts of Interest

ENBREL (Amgen-sponsored) Abstracts of Interest

Biosimilars Abstracts of Interest

Additional Abstracts of Interest

About Psoriasis Psoriasis is a non-contagious chronic disease in which the immune system causes skin cells to grow at an accelerated rate.2 Instead of being shed, skin cells pile up, causing painful and itchy, red, scaly patches.3 Approximately 125 million people worldwide have psoriasis, and 80 percent of those patients have plaque psoriasis.1,4

See the rest here:
Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy ...

Psoriasis Arthritis Treatment
Si quieres descubrir un inusual tip para la cura definitiva de la artritis entrar aqu: http://www.curediseasesinsights.com/arthritis/ Arthritis is an inflammation of one or more of your...

By: Madison Tisdale

View original post here:
Psoriasis Arthritis Treatment - Video

Ask Dr. Bob: Psoriasis, Candida, Post Brain Tumor Iodine, Grinding Teeth More
Do you know what you can do if you grind your teeth at night? Dr. Bob shares his protocol, plus answers your questions on how to help psoriasis, candida, vit...

By: DruglessDoctor

Read more:
Ask Dr. Bob: Psoriasis, Candida, Post Brain Tumor & Iodine, Grinding Teeth & More - Video

What Spice Has Anti-Inflammatory Action For Psoriasis?

By: Joint Health

See the original post here:
What Spice Has Anti-Inflammatory Action For Psoriasis? - Video

Psoriasis Free For Life - How to Cure Psoriasis Easily, Naturally and For Life Review
Go Here to learn more about this product: http://yub.me/go?psoriasis/Special.

By: James Derailler

Original post:
Psoriasis Free For Life - How to Cure Psoriasis Easily, Naturally and For Life Review - Video

Patient Testimonial - Pamela - Psoriasis
http://www.sunrisechiropracticwellnesscenter.com.

By: dbwc1

Here is the original post:
Patient Testimonial - Pamela - Psoriasis - Video

A transatlantic collaboration between scientists at Sareum in Cambridge UK and colleagues at the US research institute SRI International, holds potential for a novel psoriasis therapy.

They have developed a novel molecule that significantly decreases psoriasis pathology in a disease model a breakthrough reported in the latest edition of the Journal of Immunology.

The potential psoriasis therapy targets members of the JAK family of kinase enzymes, which control the production of cytokines. Cytokines are signalling molecules produced by the immune system, usually in response to a danger such as invading pathogens.

Cytokines responsible for psoriasis are thought to be controlled by JAK family kinases TYK2 and JAK1. Autoimmune diseases, such as psoriasis, can occur when the production of cytokines is not properly regulated and immune cells are overly activated.

In the psoriasis model system, the TYK2/JAK1 inhibitor molecule, known as SAR-20347, interrupted the psoriatic cascade of events and led to reduced activation of keratinocytes (skin cells that multiply excessively in psoriasis) and a reduction of pro-inflammatory cytokine levels.

Sareum and SRI International entered into a co-development agreement to develop TYK2 inhibitors for autoimmune and inflammatory diseases in April 2013.

Sareum's CEO Dr Tim Mitchell, said: The work reported in this publication exemplifies the success of the collaboration and the quality of research by the scientists involved. I look forward to discussing these latest advances with potential licensing partners.

Annalisa D'Andrea, senior director of Center for Immunology and Infectious Diseases in SRI's Biosciences Division, added: While we are still in the early stages of research, our success so far is encouraging, and we plan to pursue other autoimmune and inflammatory diseases that might be treated by TYK2 inhibition.

We hope to expand our TYK2-inhibitor program to address other autoimmune diseases, such as sepsis, rheumatoid arthritis and multiple sclerosis.

AIM-listed Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Read the original:
Sareum in psoriasis drug breakthrough

Psoriasis Remedies How To Cure Psoriasis Fast
Click here: http://www.sniplink.info/RHAR56 for *much* more information.

By: Reviews101

More here:
Psoriasis Remedies How To Cure Psoriasis Fast - Video

Eyelid Psoriasis Treatment
http://bit.ly/1pbwYX8 Click here now learn about getting rid of psoriasis permanently in less than a week! It #39;s fast and actually does the job. Eyelid psoria...

By: Danika Notestine

Read more:
Eyelid Psoriasis Treatment - Video

Uv Light Treatment For Psoriasis - Psoriasis Cream Cortisone
http://bit.ly/1vTI3lp Click here to learn how to cure psoriasis for good in less than 3 days. This method is easy and really does what it #39;s supposed to! Uv l...

By: Hedy Ventimiglia

Follow this link:
Uv Light Treatment For Psoriasis - Psoriasis Cream Cortisone - Video